Endocrine Metabolic Disease Risk - Moving from Concept to Clinical Trial Application
1Craven B, 2Nash M, 2Anderson-Erisman K
1Toronto Rehabilitation Institute-UHN, Toronto, Ontario, Canada; 2University of Miami Miller School of Medicine, Miami, Florida, United states
Length of Couse: 60 (Short)
Number of individuals proposed: 3
Type of Course: Best Practice Panel
Individuals living with chronic spinal cord injury (SCI) are at increased risk of developing endocrine metabolic disease (EMD) risk including sarcopenic obesity, dyslipidemia, type II diabetes and fragility fracture. Assessing an individual’s EMD risk using SCI specific guidelines and prescribing appropriate disease-modifying therapies are essential to prevent EMD related morbidity and mortality in this population. Consensus-based frameworks for EMD risk screening and treatment are needed.
This workshop will focus on EMD risk identification and highlight potential treatments. The panelists will present; 1) a model of EMD risk among individuals with SCI; 2) review current guidelines for detection and management of dyslipidemia; 3) highlight desired improvements from clinical trials by patients; and 4) statin therapy will be introduced as a promising therapy for modifying EMD risk in the chronic SCI population. Panelist will discuss the importance of implementing current standard of care into clinical trial protocols.
B. Catharine Craven, MD, BA, MD, MSc, FRCPC, CCD
Senior Scientist, Neural Engineering & Therapeutics Team, Toronto Rehab - UHN
Associate Professor, Dept. of Medicine, Division of PM&R, University of Toronto
Principal Investigator, RoBaCO Trial (NCT# NCT03113994)
Mark S. Nash, Ph.D., FACSM
Professor, Departments of Neurological Surgery and Rehabilitation Medicine
Principal Investigator, The Miami Project to Cure Paralysis Director of Research, Department of Physical Medicine & Rehabilitation University of Miami Miller School of Medicine Lois Pope Life Center
Kim Anderson-Erisman, Ph.D.
Professor, Dept. of Neurological Surgery
Director of Education, The Miami Project, University of Miami Miller School of Medicine
Craig H Neilsen Foundation Grant #350642
0:00-0:08: Overview of Endocrine Metabolic Disease in People with Chronic SCI (Craven)
0:08-0:20: Detection and Management of Dyslipidemia in People with Chronic SCI (Nash)*
0:20-0:32: What Patients Want from Clinical Trials? (Anderson-Erisman)*
0:32-0:44: Provide an Overview of the RoBaCO Trial Methods: Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes (Craven)*
0:44-0:60 Panel Discussions
* 10 min presentation +2 min question
You Must Be Logged In
This Reminders tab will display for your scheduled lectures 15 minutes before start time and for new messages waiting.